STOK

Sinker

Stoke Therapeutics, Inc. · Healthcare · United States · $1.6B cap · $31.4M/day traded

$26.68 +1.8% · close 13 Nov · scored 14 Nov

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

9
Score
Get score and insider alerts
Quality
30
Value
23
Momentum
29

As of 14 Nov 2026, the MoatMap Score for Stoke Therapeutics, Inc. (STOK) is 9/100, ranked against 25,000+ stocks in 38 markets (Quality 30, Value 23, Momentum 29, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 26.6x
ROE
-73.6%
peers -29.9%
D/E
0.0x
peers 0.2x
Dividend %
—
trailing yield

ABOUT STOKE THERAPEUTICS, INC.

Read

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) medicines to increase protein expression and treat genetic diseases caused by protein insufficiency. The company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform aims to precisely upregulate protein levels by targeting pre-mRNA, addressing conditions like Dravet syndrome and severe epilepsies. This innovative ASO technology offers a distinct competitive moat in the precision medicine field, targeting diseases at their genetic root cause.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue12.4M8.8M36.6M184.4M145.9%28.2M34.7M47.1M-49.5%
Net margin-814.7%-1192.5%-243.4%-3.7%+811.0 pts————
EPS-2.60-2.38-1.65-0.12—-3.81-4.01-4.09—
Share count39.4M45.9M54.0M58.9M14.3%65.4M———
Balance sheet
Debt2.4M2.1M2.3M3.0M8.4%1.9M———
Equity184.8M159.6M229.0M352.5M24.0%————
Debt/equity0.0x0.0x0.0x0.0x0.0x————
Cash flow
Op. cash flow-31.9M-81.1M-86.9M45.6M—-210.3M———
Cash flow margin-256.9%-923.3%-237.6%24.7%+281.6 pts-745.5%———
Investing CF-45.9M105.9M-107.5M-186.8M—————
Financing CF46.4M53.0M131.1M97.4M—————
PRICE (1Y) · USD+5.4%
22.523.825.126.427.85 Oct26 Oct13 Nov
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsBumpy

Swung more than 67% of stocks we rank over the past year (volatility 53% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$26.68
RSI (14)
57.3
52-Week Range-33.7% from high
Low $22.05High $40.22

SCORE BREAKDOWN

Quality
30
ROIC
-71.4%10.1
ROE
-73.6%12.8
GP/Assets
6.7%20.5
Op. Margin
-913.2%8.2
FCF/Assets
-51.6%7.2
Piotroski
457.9
Int. Cover
—N/A
D/E Ratio
0.01x88.0
Current Ratio
7.24x81.8
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-5.6x25.0
P/FCF
—N/A
P/B
4.9x24.9
P/S
61.9x8.0
Div Yield
—N/A
Momentum
29
52W High %
66%51.5
RS 6M
-14%36.1
SMA 50/200
0.86x26.5
EPS Rev 4W
-16.2%3.0
EPS Rev 12W
-16.9%7.5
EPS Improve
-7%19.4
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$1.6B
P/E (Forward)
-6.5x
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STOK are excluded.

TickerCompanyMkt CapScore
STOKStoke Therapeutics, Inc.(you)$1.6B9
RAREUltragenyx Pharmaceutical Inc.$1.5B10
NTLAIntellia Therapeutics, Inc.$1.6B7
TYRATyra Biosciences, Inc.$1.4B10
LYCALycia Therapeutics, Inc.$1.6B7
ADRXADARx Pharmaceuticals, Inc.$1.9B9
GENBGenerate Biomedicines, Inc.$1.6B5
KLRAKailera Therapeutics, Inc.$1.7B13
MLYSMineralys Therapeutics, Inc.$1.8B6
ABSIAbsci Corporation$1.6B15

Peer medians: ROE -29.9% · P/E 26.6x · Gross margin 63.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Stoke Therapeutics, Inc. (STOK): Stock Score Summary

Stoke Therapeutics, Inc. (STOK) has a MoatMap Score of 9/100 based on Quality (30/100), Value (23/100), and Momentum (29/100) factor scores.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) medicines to increase protein expression and treat genetic diseases caused by protein insufficiency. The company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform aims to precisely upregulate protein levels by targeting pre-mRNA, addressing conditions like Dravet syndrome and severe epilepsies. This innovative ASO technology offers a distinct competitive moat in the precision medicine field, targeting diseases at their genetic root cause.

Director dealings

From 2 Jan 2026 to 13 Nov 2026, MoatMap's records hold 27 sales and no purchases of Stoke Therapeutics, Inc. (STOK) shares by its directors. The largest: Krainer Adrian R. sold 33,243 shares at $39.74 on 10 Mar 2026 (about $1.3M).

  • 2 Nov 2026: Ticho Barry sold 7,195 shares at $26.39 (about $190K)
  • 2 Oct 2026: Allan Jonathan sold 627 shares at $26.33 (about $17K)
  • 1 Oct 2026: Ticho Barry sold 1,051 shares at $26.16 (about $27K)
  • 1 Sep 2026: Ticho Barry sold 5,545 shares at $30.67 (about $170K)
  • 18 Aug 2026: Allan Jonathan sold 2,861 shares at $32.03 (about $92K)
STOK insider filings, last 180 days

Key Financial Metrics

Price$26.68
Market Cap$1.6B
P/E (Forward)-6.53
Price/Book4.90
Return on Equity-73.6%
Return on Invested Capital-71.4%
Debt/Equity0.01x
Gross Margin100.0%
Operating Margin-913.2%
Revenue Growth5.9%
Free Cash Flow$-216M

Stoke Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Stoke Therapeutics, Inc.’s (STOK) MoatMap Score?
The MoatMap Score for Stoke Therapeutics, Inc. (STOK) is 9/100. It is a composite of Quality (30), Value (23), and Momentum (29), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Stoke Therapeutics, Inc. have an economic moat?
Stoke Therapeutics, Inc. (STOK) has a Quality factor score of 30/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Stoke Therapeutics, Inc. in?
Stoke Therapeutics, Inc. (STOK) operates in the Healthcare sector, specifically the Biotechnology industry (United States).